OPKO Health

Developing proprietary versions of proteins already approved for medical therapy.

Launch date

Mar 2007

Employees

1001-5000 people

Market cap

Enterprise valuation

€1.2b (Public information from Sep 2024)

Miami Florida (HQ)

http://www.opko.com/

http://www.facebook.com/pages/OPKO-Health/303947936433551 https://www.linkedin.com/company/opko-health-inc.

View job openings

Revenues, earnings & profits over time

USD	2020	2021	2022	2023	2024	2025	2026
Revenues	1.4b	1.8b	1.0b	863m	705m	715m	743m
% growth	59 %	24 %	(43 %)	(14 %)	(18 %)	1 %	4 %
EBITDA	106m	2.6m	(178m)	(65.8m)	(104m)	10.9m	71.2m
% EBITDA margin	7 %	-	(18 %)	(8 %)	(15 %)	2 %	10 %
Profit	30.6m	(30.1m)	(328m)	(189m)	(210m)	(202m)	(83.1m)
% profit margin	2 %	(2 %)	(33 %)	(22 %)	(30 %)	(28 %)	(11 %)
EV / revenue	1.8x	1.9x	1.0x	1.4x	1.6x	1.6x	1.6x
EV / EBITDA	24.9x	1260.0x	-5.4x	-17.7x	-11.1x	106.7x	16.3x
R&D budget	75.3m	76.8m	73.9m	89.6m	-	-	-
R&D % of revenue	5 %	4 %	7 %	10 %	-	-	-

Date	Investors	Amount	Round
-	BioAdvance	N/A	-
Jun 2007	N/A	N/A	IPO
Jun 2009	N/A	$31.0m	Post IPO Equity
Feb 2013	N/A	$175m	Post IPO Debt
Jan 2024*	N/A	$200m	Post IPO Convertible
Jul 2024*	HealthCare Royalty	$250m	Post IPO Debt
Total Funding		-

Tech stackLearn more about the technologies and tools that this company uses.

Phio Pharmaceuticals

exited

Claros Diagnostics

ACQUISITION by OPKO Health Oct 2011

ACQUISITION by OPKO Health Aug 2013

Transition Therapeutics

ACQUISITION by OPKO Health Jun 2016

Arno Therapeutics

exited

Eloxx Pharmaceuticals

ACQUISITION by Sevion Therapeutics Jun 2017

ModeX Therapeutics

ACQUISITION by OPKO Health May 2022